Markay Hopps

  • Citations Per Year
Learn More
BACKGROUND A previous fibromyalgia (FM) research reports that 20%-47% of diagnosed patients may not meet the study definition of FM 1-2 years after diagnosis. The aim of this study was to gain a better understanding of the progression of FM in a geographically diverse cohort over a 2-year time period. METHODS This cohort study followed 226 subjects(More)
AIMS Diabetic peripheral neuropathy (DPN) accompanied by painful symptoms is known as painful DPN (pDPN). This study characterized healthcare resource utilization and costs in patients with DPN, pDPN, and severe pDPN relative to diabetes only. METHODS Four adult cohorts were identified from the Humedica database: type 2 diabetes without DPN (n=288,328);(More)
Objective To identify variables correlated with a diagnosis of diabetic peripheral neuropathy (DPN) using random forest modeling applied to electronic health records. Design Retrospective analysis. Setting Humedica de-identified electronic health records database. Subjects Subjects ≥ 18 years old with type 2 diabetes from January 1, 2008-September 30,(More)
BACKGROUND Longitudinal research on outcomes of patients with fibromyalgia is limited. OBJECTIVE To assess clinician and patient-reported outcomes over time among fibromyalgia patients. METHODS At enrollment (Baseline) and follow-up (approximately 2 years later), consented patients were screened for chronic widespread pain (CWP), attended a physician(More)
Background The prevalence of neuropathic pain (NeP) has been estimated within specific health conditions; however, there are no published data on its broad prevalence in the US. The current exploratory study addresses this gap using the validated PainDetect questionnaire as a screener for probable NeP in a general-population health survey conducted with a(More)
OBJECTIVES The aim of this study was to evaluate relationships between serum uric acid (SUA) and newly emergent acute myocardial infarction (AMI), congestive heart failure (CHF), coronary artery disease (CAD), composite cardiovascular (CV) events (AMI, CHF, CAD), hypertension, hyperlipidemia, and renal disease in gout patients. METHODS Retrospective(More)